BRPI0415899A - uses of a compound, and an h3 receptor antagonist, inverse agonist or partial agonist, pharmaceutical composition, method for identifying compounds useful for treating disease, and compound - Google Patents
uses of a compound, and an h3 receptor antagonist, inverse agonist or partial agonist, pharmaceutical composition, method for identifying compounds useful for treating disease, and compoundInfo
- Publication number
- BRPI0415899A BRPI0415899A BRPI0415899-7A BRPI0415899A BRPI0415899A BR PI0415899 A BRPI0415899 A BR PI0415899A BR PI0415899 A BRPI0415899 A BR PI0415899A BR PI0415899 A BRPI0415899 A BR PI0415899A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disorder
- disorders
- pharmaceutical composition
- agonist
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 239000004031 partial agonist Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 title abstract 2
- 229940125425 inverse agonist Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002469 receptor inverse agonist Substances 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 abstract 1
- 208000026345 acute stress disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019899 phobic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"USOS DE UM COMPOSTO, E DE UM ANTAGONISTA DE RECEPTOR DE H~ 3~, AGONISTA INVERSO OU AGONISTA PARCIAL, COMPOSIçãO FARMACêUTICA, MéTODO PARA A IDENTIFICAçãO DE COMPOSTOS úTEIS PARA O TRATAMENTO DE DOENçAS, E, COMPOSTO". A invenção refere-se ao uso de um composto, que é um inibidor da recaptação de serotonina, e de outro composto, que é um antagonista de receptor de H~ 3~, agonista inverso ou agonista parcial para a preparação de uma composição farmacêutica para o tratamento de doenças, tais como, depressão, distúrbios de ansiedade e de outros distúrbios afetivos, tais como distúrbio de ansiedade generalizada, ansiedade de pânico, distúrbio obsessivo compulsivo, distúrbio de estresse agudo, distúrbio de estresse pós-traumático e distúrbio de ansiedade social, distúrbios de alimentação tais como bulimia, anorexia e obesidade, fobias, distimia, sindrome pré-menstrual, distúrbios cognitivos, distúrbios de controle impulsivo, distúrbio de hiperatividade com deficiência de atenção, abuso de droga ou qualquer outro distúrbio responsivo ao inibidor da recaptação de serotonina."USES OF A COMPOUND, AND A H ~ 3 ~ RECEIVER ANTAGONIST, INVERTER AGENT, OR PARTIAL AGONIST, PHARMACEUTICAL COMPOSITION, METHOD FOR IDENTIFYING COMPOUNDS FOR DISEASE TREATMENT," The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and of another compound, which is a H 3 -receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for treating diseases such as depression, anxiety disorders and other affective disorders such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, posttraumatic stress disorder and social anxiety disorder , eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulsive control disorders, attention deficit hyperactivity disorder, drug abuse, or any other responsive to reuptake inhibitor disorder serotonin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52949103P | 2003-12-15 | 2003-12-15 | |
| DKPA200301854 | 2003-12-15 | ||
| PCT/DK2004/000862 WO2005056056A2 (en) | 2003-12-15 | 2004-12-14 | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0415899A true BRPI0415899A (en) | 2007-01-09 |
Family
ID=34680191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415899-7A BRPI0415899A (en) | 2003-12-15 | 2004-12-14 | uses of a compound, and an h3 receptor antagonist, inverse agonist or partial agonist, pharmaceutical composition, method for identifying compounds useful for treating disease, and compound |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1696896A2 (en) |
| JP (1) | JP2007513896A (en) |
| AU (1) | AU2004296531A1 (en) |
| BR (1) | BRPI0415899A (en) |
| NO (1) | NO20063267L (en) |
| WO (1) | WO2005056056A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG146683A1 (en) | 2003-09-17 | 2008-10-30 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as serotonin receptor modulators |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| CN101809021B (en) | 2007-09-11 | 2013-04-24 | 雅培制药有限公司 | Octahydro-pyrrolo[3,4-B]pyrrole N-oxide |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| JP7579028B2 (en) * | 2020-12-23 | 2024-11-07 | 上海雲晟研新生物科技有限公司 | Vilazodone pharmaceutical composition, its preparation method and application |
| AU2024230525A1 (en) * | 2023-02-28 | 2025-10-09 | Biohaven Therapeutics Ltd. | Methods for treating obsessive compulsive related disorders, tic disorders and glutamate excitotoxicity related disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020279A1 (en) * | 1997-10-17 | 1999-04-29 | Eli Lilly And Company | Potentiation of pharmaceuticals |
| HK1040055B (en) * | 1998-05-22 | 2005-04-01 | 伊莱利利公司 | Use of olanzapine and fluoxetine in the preparation of a medicament for the treatment of treatment resistant major depression |
| BR9911068A (en) * | 1998-05-29 | 2001-02-06 | Lilly Co Eli | Combination therapy for the treatment of bipolar disorders |
| EP0978512A1 (en) * | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications |
-
2004
- 2004-12-14 WO PCT/DK2004/000862 patent/WO2005056056A2/en not_active Ceased
- 2004-12-14 AU AU2004296531A patent/AU2004296531A1/en not_active Abandoned
- 2004-12-14 EP EP04803015A patent/EP1696896A2/en not_active Withdrawn
- 2004-12-14 JP JP2006543369A patent/JP2007513896A/en not_active Withdrawn
- 2004-12-14 BR BRPI0415899-7A patent/BRPI0415899A/en not_active IP Right Cessation
-
2006
- 2006-07-13 NO NO20063267A patent/NO20063267L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004296531A1 (en) | 2005-06-23 |
| EP1696896A2 (en) | 2006-09-06 |
| JP2007513896A (en) | 2007-05-31 |
| WO2005056056A2 (en) | 2005-06-23 |
| WO2005056056A3 (en) | 2006-02-02 |
| NO20063267L (en) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0212733B8 (en) | pharmaceutical composition comprising serotonin reuptake inhibitor compound, and use thereof | |
| BRPI0413563A (en) | compounds and compositions as inhibitors of tyrosine kinase receptor activity | |
| BR0311503A (en) | Use of a compound, use of a partial agonist, inverse agonist, or gabab receptor antagonist, pharmaceutical composition, method for identifying compounds useful for treating disease, and compound | |
| BR0016385A (en) | Compounds or combinations thereof which have seratonin reuptake inhibitory activity and a 5-ht2c antagonist, inverse agonist or partial agonist; use thereof; pharmaceutical composition and method | |
| BRPI0410235A (en) | pde4 inhibition, compound, pharmaceutical composition, method for inhibiting pde4 enzyme, enhancing cognition and / or treating psychosis in a patient, method for treating a patient having a disease involving decreased camp levels, method for the treatment of a patient suffering from an allergic or inflammatory disease and method for the treatment of a patient suffering from neurodegeneration resulting from an illness or injury | |
| BRPI0518798A2 (en) | compound, pharmaceutical composition, and methods for treating type II diabetes and for treating a condition or disorder | |
| CY1108060T1 (en) | CARBOSTYRIL PRODUCTS AND SEROTONINE REHABILITATION INHIBITORS FOR TREATMENT DISORDERS | |
| EA200001218A1 (en) | COMBINATION THERAPY FOR THE TREATMENT OF RESISTANT DEPRESSION | |
| NO20051769L (en) | Antidepressant Azaheterocycyl Methyl Derivatives of Heterocycle Condensed Benzodioxanes | |
| BR0306147A (en) | Use of a compound or combination of compounds having partial dopamine-d2 receptor agonistic activity and serotonin and / or norepinephrine reuptake inhibiting activity, method for preparing a composition, and, composition | |
| ATE459353T1 (en) | GABOXADOL USED TO TREAT DEPRESSION AND OTHER AFFECTIVE DISORDERS | |
| BRPI0512869A (en) | compound, pharmaceutical composition, and method of treating a disease, disorder and / or condition in a patient | |
| BRPI0512742A (en) | compound, pharmaceutical composition, and method of treating a disease, disorder and / or condition in a patient in which modulation of a 5-ht2c function is desired | |
| JP2007513052A5 (en) | ||
| ATE281459T1 (en) | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO(2,3-F)QUINOLINE AS ANTIDEPRESSANTS | |
| BRPI0413587A (en) | Uses of a Glyt-1 Compound and Inhibitor, Pharmaceutical Composition, Kit, and, Disease Treatment Method | |
| WO2005056056A3 (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
| ATE312094T1 (en) | NEW HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | |
| EA200601158A1 (en) | COMBINATION OF SEROTONIN RETURN CAPTURE INHIBITOR AND ANTAGONIST, REVERSE AGONIST OR PARTIAL AGONIST OF HISTAMINE 3 RECEPTOR | |
| BR0314513A (en) | Heterocycle-fused benzodioxane antidepressant indolealkyl antidepressant derivatives | |
| BRPI0412268A (en) | compounds containing a selective serotonin reuptake inhibitor and 5-ht2a receptor antagonist | |
| UA84692C2 (en) | Pharmaceutical composition, comprising aripiprazole and serotonin reuptake inhibitor, and the use thereof for treatment of mood disorders | |
| BR0314430A (en) | Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxanes | |
| BR0314431A (en) | Antidepressant piperidine derivatives of heterocyl-fused benzodioxanes | |
| AR039723A1 (en) | COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S) |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |